Human CNR1 Full Length Protein (VLP)

ユーザーレビュー
製品番号/仕様
価格
数量
CN1-H52P6-20ug
$620.00
CN1-H52P6-100ug
$1235.00
CN1-H52P6-500ug (250ug X 2)
$4305.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Application

    1. Immunization
    2. Cell based assay (FACS or functional assay)
    3. Screening (ELISA)
  • Synonyms

    CNR1, cannabinoid receptor 1, CANN6, CB-R, CB1, CB1A, CB1K5, CB1R, CNR

  • Source

    Human CNR1 Full Length Protein-VLP (CN1-H52P6) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Lys 472 (Accession # P21554-1 (T210A)).

    Predicted N-terminus: Asp

  • Molecular Characterization

    *The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

    2. Synthesis Process

      Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SEC-HPLC.

  • Formulation

    The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

    Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 12 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SEC-HPLC

    CNR1 SEC-HPLC

    The purity of Human CNR1 Full Length Protein-VLP (Cat. No. CN1-H52P6) was greater than 95% as determined by SEC-HPLC.

  • Bioactivity-ELISA

     CNR1 ELISA

    Immobilized Human CNR1 Full Length Protein-VLP (Cat. No. CN1-H52P6) at 5 μg/mL (100 μL/well) can bind Human Anti-CNR1,Human IgG4 | Human Kappa with a linear range of 1-31 ng/mL (QC tested).

    Protocol
  • Identity-DLS

     CNR1 DLS

    The mean peak Radius of VLP is 45-70 nm with more than 95% intensity as determined by dynamic light scattering (DLS).

ユーザーレビュー
コメントを投稿

バックグランド

The Cannabinoid Receptor 1 (CB1), a CNS-abundant GPCR mediating psychoactive effects of THC and regulating appetite, pain, and mood. Peripheral CB1 inverse agonism is a promising strategy for treating metabolic syndrome and liver fibrosis, aiming to recapitulate metabolic benefits without the CNS side effects of rimonabant.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    Cannabinoid CB1 receptor

  • カテゴリ:

  • 市販の医薬品数:

    2 詳細

  • 治験医薬品数:

    38 詳細

  • 最新の開発ステージ:

    Approved

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8